Predictive Oncology Reports Third Quarter 2020 Financial Results, Provides Business UpdateGlobeNewsWire • 11/16/20
Predictive Oncology Inc. CEO Provides Updates on Subsidiaries, Highlights Recent Milestones and Near-Term GoalsGlobeNewsWire • 10/27/20
Predictive Oncology Secures License for an Additional 71 Unique Ovarian Cancer Cell Lines from Ximbio, Cancer Research UK’s Premier Reagents DistributorGlobeNewsWire • 09/22/20
Predictive Oncology Inc to Present at LD Micro's "LD 500" Virtual Investor Conference on Wednesday, September 02, 2020 3:40 PM Eastern TimeGlobeNewsWire • 09/01/20
Soluble Biotech Announces First Contract with a Major Pharmaceutical Company for Protein Expression and Solubility StudiesGlobeNewsWire • 08/20/20
Predictive Oncology’s Skyline Medical Sells 8 STREAMWAY® Systems to a Large University Hospital Organization in Virginia; 13 STREAMWAY® Systems Sold Halfway Into Q3 2020GlobeNewsWire • 08/18/20
Predictive Oncology Announces DojoLIVE! Interview with Helomics CIO Mark Collins, ‘Can We Cure Cancer with Artificial Intelligence?GlobeNewsWire • 08/14/20
Predictive Oncology Reports Second Quarter 2020 Financial Results, Provides Business UpdateGlobeNewsWire • 08/13/20
Predictive Oncology Inc. Announces Receipt of Cash Proceeds of $2.2 Million from Exercise of WarrantsGlobeNewsWire • 06/29/20
Predictive Oncology’s TumorGenesis Division Secures First Commercial Sale of its Novel Ovarian Cancer Cell MediaGlobeNewsWire • 06/18/20
Predictive Oncology Reports First Quarter 2020 Financial Results, Provides Business UpdateGlobeNewsWire • 06/08/20
Predictive Oncology Completes Acquisition of Soluble Therapeutics and BioDtechGlobeNewsWire • 06/02/20
Predictive Oncology (NASDAQ Symbol POAI) is licensing and partnering this groundbreaking NSP10 technology in the race to develop a vaccine for developmentGlobeNewsWire • 05/14/20
Predictive Oncology Announces $2.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq RulesGlobeNewsWire • 05/07/20
Predictive Oncology and Dr. Daniel Carter Collaborating to Develop a Potential COVID-19 Vaccine Utilizing Novel Nanoparticle Vaccine Platform, Based on NSP-10GlobeNewsWire • 05/06/20
Predictive Oncology Exchanges $2.1 Million of Debt for Equity, Streamlining Capital Structure and Simplifying Balance SheetGlobeNewsWire • 04/22/20
Predictive Oncology (NASDAQ: POAI) CEO Discusses ‘Major Asset’ in Exclusive InterviewGlobeNewsWire • 04/22/20
POAI Subsidiary Helomics Continues Progress Towards Goal of Developing an AI-Driven Predictive Model of Ovarian CancerGlobeNewsWire • 03/31/20
Predictive Oncology Inc. Announces Completion of $3.5 Million Private PlacementGlobeNewsWire • 03/23/20
Predictive Oncology Launches New AI Platform for Vaccine and Drug Development Targeting Coronaviruses and Acute Respiratory Syndromes (COVID-19, MERS, and SARS)GlobeNewsWire • 03/12/20
Predictive Oncology Provides Acquisition Update, Stresses Importance of AI in New Anti-Cancers, Anti-Virals and VaccinesGlobeNewsWire • 03/02/20